Rationale for the use of aldosterone antagonists in congestive heart failure

Drugs

Volumn 62, Issue 5, 2002, Pages 723-731

  Rocha, Ricardo ^a   Williams, Gordon H ^b  

^a PFIZER INC   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; CELL NUCLEUS RECEPTOR; CORTICOTROPIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; PLACEBO; POTASSIUM; SODIUM PROTON EXCHANGE PROTEIN; SPIRONOLACTONE;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; EPITHELIUM CELL; HEART INJURY; HEMODYNAMICS; HORMONAL REGULATION; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY; LEUKOCYTE; NONHUMAN; PATHOPHYSIOLOGY; POTASSIUM EXCRETION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SECOND MESSENGER; SODIUM ABSORPTION; VASCULAR SMOOTH MUSCLE;

EID: 0036252645     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262050-00001     Document Type: Review

References (55)

1. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
2. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation
3. Aldosterone biosynthesis in the rat brain
4. Vascular aldosterone in genetically hypertensive rats
5. The nuclear receptor superfamily: The second decade
6. The role of heat shock proteins in regulating the function, folding and trafficking of the glucocorticoid receptor
7. Subcellular localization of mineralocorticoid receptors in living cells: Effects of receptor agonists and antagonists
8. Glucocorticoid receptor, mineralocorticoid receptors, 11 beta-hydroxysteroid dehydrogenase-1 and -2 expression in rat brain and kidney: In situ studies
9. Prerequisite for cardiac aldosterone action: Mineralocorticoid receptor and 11 β-hydroxysteroid dehydrogenase in the human heart
10. 11 beta-Hydroxysteroid dehydrogenase: New answers, new questions
11. The serum- and glucocorticoid-induced kinase is a physiological mediator of aldosterone action
12. Role of renal hemodynamics and arterial pressure in aldosterone 'escape'
13. Sodium excretion and atrial natriuretic peptide levels during mineralocorticoid administration. A mechanism for the escape from hyperaldosteronism
14. The renal thiazidesensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon
15. High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes
16. Hyperaldosteronemia in rabbits inhibits the cardiac sarcolemmal Na(+)-K(+) pump
17. Protein Kinase C-ε regulates cardiac Na+-K+ pump function in hyperaldosteronemia
18. Effects of aldosterone and spironolactone on the isolated perfused rat heart
19. Aldosterone upregulates Ca(2+) current in adult rat cardiomyocytes
20. Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors
21. Rapid effects of aldosterone on sodium transport in vascular smooth muscle cells
22. Role of 11beta-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries
23. Potentiation of angiotensin II action by corticosteroids in vascular tissue
24. Non-genomic action of the mineralocorticoid aldosterone on cytosolic sodium in cultured kidney cells
25. Volumes and Na+/H+ antiporter activity of lymphocytes in patients with congestive heart failure
26. Rapid non-genomic feedback effects of glucocorticoids on CRF-induced ACTH secretion in rats
27. Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells
28. The production of cardiac lesions by repeated injections of deoxycorticosterone acetate
29. Malignant hypertension produced by treatment with deoxycorticosterone acetate and sodium chloride
30. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy
31. Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone
32. Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury
33. Remodeling of the right and left ventricles in experimental hypertension
34. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states
35. Collagen metabolism in cultured adult rat cardiac fibroblasts: Response to angiotensin II and aldosterone
36. Aldosterone and cardiac fibrosis: In vitro studies
37. Does aldosterone-induced cardiac fibrosis involve direct effects on cardiac fibroblasts?
38. Biological determinants of aldosterone-induced cardiac fibrosis in rats
39. Aldosterone induces a vascular inflammatory phenotype in the rat heart
40. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality
41. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension
42. Associations between circulating components of the renin-angiotensin-aldosterone-system and left ventricular mass
43. Primary aldosteronism and its variants
44. Clinical characteristics of primary aldosteronism from an analysis of 145 cases
45. Renal abnormalities and vascular complications in primary aldosteronism: Evidence of tertiary hyperaldosteronism
46. Cardiovascular complications in patients with primary aldosteronism
47. Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheochromocytoma
48. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism
49. Free estradiol increase with concomitant decrease of free testosterone in plasma from normal men after incubation with spironolactone
50. Eplerenone: A Selective Aldosterone Receptor Antagonist (SARA)
51. Spironolactone in the long-term management of patients with congestive heart failure
52. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
53. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression
54. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study
55. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy